Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3
The experimentally established mechanism targets of Carvedilol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.86 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.86 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.86 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.86 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.86 |
| ▸ | DRD2 | P14416 | 3/20 | 0.86 |
| ▸ | TLR4 | O00206 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.86 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.86 |
| ▸ | MLNR | O43193 | 1/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.86 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | APP | P05067 | 1/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carvedilol SCHEMBL975401 | 0.94 | ADRB2 (0.91) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL10082334 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL29744884 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL29370188 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL1172788 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| (R)-Carvedilol SCHEMBL232110 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| (R)-Carvedilol SCHEMBL29382761 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| (R)-Carvedilol SCHEMBL29744872 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL1560204 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 | |
| Carvedilol SCHEMBL29687280 | 0.93 | ADRB2 (1.00) | ADRB2DRD2TLR4MAPTDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750036-B2 | carvedilol mandelate or carvedilol sulfate salt for treating hypertension, congestive heart failure or angina cardiovascular disorders | SB PHARMCO PUERTO RICO INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1686986-A4 | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF DELIVERY AND/OR TREATMENT | SB PHARMCO INC (US) | 2009-05-27 | — | — | EP | claimed |
| US-20090028935-A1 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2009-01-29 | — | — | US | claimed |
| WO-2008070072-A2 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-06-12 | — | — | WO | claimed |
| JP-2007512372-A | — | — | 2007-05-17 | — | — | JP | claimed |
| EP-1691789-A2 | CARVEDILOL FREE BASE, SALTS, ANHYDROUS FORMS OR SOLVATE THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULATIONS, AND TREATMENT OR DELIVERY METHODS | SB Pharmco Puerto Rico Inc (PR) | 2006-08-23 | — | — | EP | claimed |
| US-20060182804-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2006-08-17 | — | — | US | claimed |
| EP-1686967-A2 | CARVEDILOL FREE BASE, SALTS, ANHYDROUS FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULATIONS, AND TREATMENT OR DELIVERY METHODS | SB Pharmco Puerto Rico Inc (PR) | 2006-08-09 | — | — | EP | claimed |
| EP-1686986-A1 | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF DELIVERY AND/OR TREATMENT | SB Pharmco Puerto Rico Inc (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050277689-A1 | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment | SB PHARMCO PUERTO RICO INC. (PR) | 2005-12-15 | — | — | US | claimed |
| US-20050175695-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-08-11 | — | — | US | claimed |
| US-20050169994-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | BURKE MATTHEW D (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005051325-A2 | CARVEDILOL COMPOSITIONS METHODS OF TREATMENT AND DELIVERY | SB PHARMCO PUERTO RICO INC. (PR) | 2005-06-09 | — | — | WO | claimed |
| WO-2005051322-A2 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING CARVEDILOL, FREE BASED AND ITS SALTS | SB PHARMCO PUERTO RICO INC. (PR) | 2005-06-09 | — | — | WO | claimed |
| WO-2005051383-A1 | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF DELIVERY AND/OR TREATMENT | SB PHARMCO PUERTO RICO INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-2471519-B1 | CONTROLLED RELEASE FORMULATION OF CARVEDILOL | SHANDONG NEW TIME PHARMACEUTICAL CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| EP-1691789-B1 | CARVEDILOL FREE BASE, SALTS, ANHYDROUS FORMS OR SOLVATE THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULATIONS, AND TREATMENT OR DELIVERY METHODS | SMITHKLINE BEECHAM (CORK) LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2005051325-A2 | CARVEDILOL COMPOSITIONS METHODS OF TREATMENT AND DELIVERY | SB PHARMCO PUERTO RICO INC. (PR) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051322-A2 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING CARVEDILOL, FREE BASED AND ITS SALTS | SB PHARMCO PUERTO RICO INC. (PR) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051383-A1 | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF DELIVERY AND/OR TREATMENT | SB PHARMCO PUERTO RICO INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050175695-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | AGTR2, ADRB1, AGTR1 | ADRB2 5/4885ADRB3 6/4885ADRB1 2/4885 |
| US-20060182804-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB3 3/4885ADRB1 2/4885 |
| US-20050169994-A1 | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB3 3/4885ADRB1 2/4885 |
| US-20050277689-A1 | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment | ADRB3, ADRB1, ADRB2 | ADRB2 3/4885ADRB3 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.